Emotional Backdrop Smolders As FDA Reviews Smoking Cessation Category
This article was originally published in The Pink Sheet & The Rose Sheet
Executive Summary
FDA asks for comments including evidence needed to show safety and efficacy for novel nicotine replacement therapies, but speakers at recent hearing highlight the public's psychological toll from tobacco-related deaths and the emotional connection smokers have with tobacco and nicotine.
You may also be interested in...
US Smoking Cessation Clinical Trials Guidance ‘Does Not Envision’ Flexibility On Indications
FDA final guidance maintains limit on secondary endpoints allowed for trials, which could dissuade some investment in research for NDAs for smoking cessation products. NRT developers could find more room for novel product proposals from changes to some phrasing.
US Smoking Cessation Clinical Trials Guidance 'Does Not Envision' Flexibility On Indications
FDA final guidance maintains limit on secondary endpoints allowed for trials, which could dissuade some investment in research for NDAs for smoking cessation products. NRT developers could find more room for novel product proposals from changes to some phrasing.
E-Cigarette Study Suggests Not Limiting Cessation Research To Smokers Interested In Quitting
JAMA study results could spur additional research with subjects from broader pool of candidates for determining whether ENDS products have potential for approval as NRT products. Studies typically limit participants to consumers who want to quit, but expanding pool to include those not interested could add to research results more instances of successful quitting.